Introduction: A Sinister Profit Scheme?
BlackRock, the financial titan, stands accused of turning children’s innocence into a $771 million jackpot through its stake in Eli Lilly, a pharma giant pushing “gender-affirming care” for minors. This isn’t just business—it’s a calculated attack on youth and the foundations of Western society, critics warn.
Eli Lilly and BlackRock: A Lucrative Partnership
Eli Lilly, a key player in hormone treatments and puberty blockers, has become a goldmine for BlackRock, which holds a significant share (IPJC Report). Reports claim BlackRock’s investment has netted $771 million, capitalizing on what City Journal calls a “fundamentally flawed” industry targeting vulnerable kids.
The Moral Crisis of Transitioning Minors
The UK’s Cass Review found evidence for these treatments’ safety is “remarkably weak,” yet the push continues, driven by profit. Free Beacon exposes how Big Pharma, including Eli Lilly, collaborates with activists to entrench gender ideology in hospitals, while BlackRock cashes in. Critics argue this exploits confused youth, leading to regret, infertility, and lifelong medical dependency.
A Threat to Western Values
Beyond profits, this agenda threatens the traditional family, a cornerstone of Western civilization. Figures like Minnesota’s Tim Walz amplify it, while Fox News shares detransitioners’ trauma stories. X posts echo the outrage: “BlackRock’s making a fortune transitioning kids”—a claim fueled by the industry’s opacity.
Conclusion: A Call to Resist
BlackRock’s $771 million windfall isn’t just money—it’s a ledger of lost innocence. As the West faces this moral siege, 2025 could be a turning point. Will we let profit-driven elites reshape society, or fight to protect our children?
